TiGenix obtains manufacturing license for European production facility

24-Apr-2012 - Belgium

TiGenix announced that further to the cGMP inspection by the Dutch authorities it has obtained the manufacturing authorization for human medicinal products for its European manufacturing plant in Sittard-Geleen in the Netherlands.

"I'd like to commend our manufacturing team responsible for building and validating our production plant in record time and passing the inspection of the Dutch regulatory authorities with flying colors," said Eduardo Bravo, CEO of TiGenix. "Our state-of-the-art manufacturing site is unique in Europe as it is 100% geared towards the production of innovative cell therapy products. It provides us with crucial manufacturing capabilities to support the anticipated growth in demand for ChondroCelect for cartilage repair, and has sufficient capacity for the production of our advanced stem cell therapy products."

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances